[go: up one dir, main page]

NO995268L - Proteaseinhibitorer - Google Patents

Proteaseinhibitorer

Info

Publication number
NO995268L
NO995268L NO995268A NO995268A NO995268L NO 995268 L NO995268 L NO 995268L NO 995268 A NO995268 A NO 995268A NO 995268 A NO995268 A NO 995268A NO 995268 L NO995268 L NO 995268L
Authority
NO
Norway
Prior art keywords
disease
protease inhibitors
compounds
arthritis
periodontitis
Prior art date
Application number
NO995268A
Other languages
English (en)
Other versions
NO995268D0 (no
Inventor
Stacie Marie Halbert
Evelyne Michaud
Scott Kevin Thompson
Daniel Frank Veber
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO995268D0 publication Critical patent/NO995268D0/no
Publication of NO995268L publication Critical patent/NO995268L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Den foreliggende oppfinnelsen tilveiebringer forbindelser med Formel l som hemmer proteaser, inkludert cathepsin K, farmasøytiske blandinger av slike forbindelser, og fremgangsmåter for behandling av sykdommer med for høyt beintap eller brusk- eller matriksnedbrytning, innbefattende osteoporose; tannkjøttsykdom innbefattende gingivitt og periodontitt; artritt, mer spesifikt osteoartritt og reumatoid artritt; Fagets sykdom; malign hyperkalsemi; og metabolsk beinsykdom dermed.
NO995268A 1997-04-29 1999-10-28 Proteaseinhibitorer NO995268L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4506797P 1997-04-29 1997-04-29
PCT/US1998/008740 WO1998048799A1 (en) 1997-04-29 1998-04-29 Protease inhibitors

Publications (2)

Publication Number Publication Date
NO995268D0 NO995268D0 (no) 1999-10-28
NO995268L true NO995268L (no) 1999-11-15

Family

ID=21935831

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995268A NO995268L (no) 1997-04-29 1999-10-28 Proteaseinhibitorer

Country Status (18)

Country Link
EP (1) EP1019046A4 (no)
JP (1) JP2002504097A (no)
KR (1) KR20010020391A (no)
CN (1) CN1261276A (no)
AR (1) AR012622A1 (no)
AU (1) AU7365198A (no)
BR (1) BR9809333A (no)
CA (1) CA2287989A1 (no)
CO (1) CO4940477A1 (no)
HU (1) HUP0001294A3 (no)
IL (1) IL132629A0 (no)
MA (1) MA26487A1 (no)
NO (1) NO995268L (no)
PE (1) PE69099A1 (no)
PL (1) PL337725A1 (no)
TR (1) TR199902703T2 (no)
WO (1) WO1998048799A1 (no)
ZA (1) ZA983522B (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1037639A4 (en) 1997-12-19 2002-04-17 Smithkline Beecham Corp HETEROARYL-SUBSTITUTED IMIDAZOLE COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITIONS AND USES
US6100282A (en) * 1998-01-02 2000-08-08 Hoffman-La Roche Inc. Thiazole derivatives
MA26618A1 (fr) * 1998-04-09 2004-12-20 Smithkline Beecham Corp Composes et compositions pharmaceutiques pour le traitement du paludisme
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
JP2002528506A (ja) 1998-11-04 2002-09-03 スミスクライン・ビーチャム・コーポレイション ピリジン−4−イルまたはピリミジン−4−イル置換ピラジン
CO5150165A1 (es) * 1998-11-13 2002-04-29 Smithkline Beecham Plc Inhibidores de proteasa: tipo catepsina k
US20030144175A1 (en) 1998-12-23 2003-07-31 Smithkline Beecham Corporation Protease inhibitors
US6583137B1 (en) 1999-11-10 2003-06-24 Smithkline Beecham Corporation Protease inhibitors
US6534498B1 (en) 1999-11-10 2003-03-18 Smithkline Beecham Corporation Protease inhibitors
AU1588901A (en) 1999-11-10 2001-06-06 Smithkline Beecham Corporation Protease inhibitors
AU1783201A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
AU1782301A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p39 kinase inhibitors
US6797720B2 (en) 1999-12-03 2004-09-28 Ono Pharmaceutical Co., Ltd. 1,3,4-oxadiazoline derivative and an agent comprising its derivative as active ingredient
WO2001040204A1 (en) * 1999-12-03 2001-06-07 Ono Pharmaceutical Co., Ltd. 1,3,4-oxadiazoline derivatives and drugs containing these derivatives as the active ingredient
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
OA12323A (en) 2000-03-21 2006-05-15 Smithkline Beecham Corp Protease inhibitors.
JP2005515254A (ja) 2002-01-17 2005-05-26 スミスクライン ビーチャム コーポレーション カテプシンk阻害剤として有用なシクロアルキルケトアミド誘導体
ATE397597T1 (de) * 2002-07-04 2008-06-15 Aventis Pharma Sa Neue thiophenacylhydrazinoderivate, verfahren zu deren herstellung, deren verwendung als arzneimittel, pharmazeutische zusammensetzungen und neue anwendungen
KR100962972B1 (ko) 2002-07-26 2010-06-09 주식회사유한양행 1-페닐피페리딘-3-온 유도체 및 그의 제조방법
WO2011015524A2 (en) * 2009-08-03 2011-02-10 Bayer Cropscience Ag Fungicide heterocycles derivatives
KR20150046259A (ko) * 2012-08-23 2015-04-29 앨리오스 바이오파마 인크. 파라믹소바이러스 바이러스성 감염의 치료용 화합물
JP6485817B2 (ja) 2013-08-21 2019-03-20 ヤンセン バイオファーマ インク. 抗ウイルス化合物
MA41614A (fr) 2015-02-25 2018-01-02 Alios Biopharma Inc Composés antiviraux

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990067184A (ko) * 1995-10-30 1999-08-16 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 프로테아제 억제제

Also Published As

Publication number Publication date
ZA983522B (en) 1998-10-29
CA2287989A1 (en) 1998-11-05
TR199902703T2 (xx) 2000-02-21
EP1019046A4 (en) 2002-11-27
IL132629A0 (en) 2001-03-19
BR9809333A (pt) 2000-07-04
AR012622A1 (es) 2000-11-08
PL337725A1 (en) 2000-08-28
HUP0001294A3 (en) 2001-06-28
CO4940477A1 (es) 2000-07-24
HUP0001294A2 (hu) 2001-04-28
EP1019046A1 (en) 2000-07-19
NO995268D0 (no) 1999-10-28
WO1998048799A1 (en) 1998-11-05
AU7365198A (en) 1998-11-24
KR20010020391A (ko) 2001-03-15
JP2002504097A (ja) 2002-02-05
MA26487A1 (fr) 2004-12-20
PE69099A1 (es) 1999-09-26
CN1261276A (zh) 2000-07-26

Similar Documents

Publication Publication Date Title
NO995268L (no) Proteaseinhibitorer
EA199800353A1 (ru) Ингибиторы протеаз
ATE411294T1 (de) 4-amino-azepan-3-on-derivate als protease- inhibitors
EA200201001A1 (ru) Ингибиторы протеаз
NZ537853A (en) Inhibitors of cathepsin K and related cysteine protesases of the CA clan
BR9804437A (pt) Compostos para a osteoporose
NZ319090A (en) (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
CL2003001743A1 (es) Compuestos derivados de leucinamida, inhibidores de la cisteina proteasa; composicion farmaceutica; procedimiento de preparacion de la composicion farmaceutica; y su uso en el tratamiento de la osteoporosis, enfermedad de paget's, peridontal, perdida
WO1999059526A3 (en) Protease inhibitors
EA200300018A1 (ru) Ингибиторы протеаз
CA2266759A1 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
DE69816047D1 (en) (methylsulfonyl)phenyl-2-(5h)-furanone mit sauerstoff-bindung als cox-2-hemmer
HK1042695A1 (zh) 蛋白酶抑制剂
HK1041690A1 (zh) 蛋白酶抑制剂
HK1044758A1 (zh) 蛋白酶抑制剂
WO2002092563A3 (en) Protease inhibitors
WO2003053331A3 (en) Protease inhibitors
TR199902564T2 (xx) K�k�rdak oligomer matris proteininin romatoid artrit tedavisinde kullan�m�.
NZ324101A (en) Protease inhibitors, pharmaceutical compositions and use thereof
BR0015482A (pt) Antagonistas de difenil leucotrieno de heterociclo substituìdo
ECSP982481A (es) Inhibidores de proteasas
AR004703A1 (es) Hidrazidil, bis-hidrazil y bis-aminometil-carbonil, inhibidores de proteasas, una composicin farmaceutica, metodo para inhibir proteasas, y uso en la preparacion de medicamentos.
ECSP003403A (es) Inhibidores de proteasas xi
ID27964A (id) Turuna-azabisikloheptana n-tersubstitusi, pembuatan dan penggunaannya
ECSP992959A (es) Inhibidores de proteasa de bis- aminometil carbonilo

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application